Yongjun Wang
Beijing Tiantan Hospital
Emerging Leaders
not ranked
Current Leaders
#3743 pts
All-Time Leaders
#24734 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2013. 11 trials as lead/chair. How it works →
Trials led — by scientific impact
A Multicenter, Randomized, Open-label, Parallel-controlled, Event-driven, Blinded-endpoint Trial Evaluating the Efficacy and Safety of Ongericimab Injection in High-risk Stroke Patients With Intracranial or Extracranial Atherosclerotic Stenosis.
Phase 3Not Yet RecruitingBeijing Tiantan Hospital
7
impact
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)
N/ARecruitingBeijing Tiantan Hospital
5
impact
Folic Acid and Intensive Antihypertensive Therapy for Cerebrovascular and Cardiovascular Events Prevention Among Patients With Hypertension and Cerebral Small Vascular Diseases (FAITH)----A Multicenter, Randomized, Controlled, Open-label, 2x2 Factorial, Blinded End-point Trial
Phase 4Not Yet RecruitingBeijing Tiantan Hospital
4
impact
A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic Stroke
Phase 3CompletedAngde Biotech Pharmaceutical Co., Ltd.
3
impact
Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2)
Phase 3CompletedBeijing Tiantan Hospital
3
impact
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 Improving Neurological Functional Outcomes in Basilar Artery Occlusion With Tenecteplase in Extended Time Window: Multicentre, Prospective, Open-label, Blinded Endpoint (PROBE), Phase 3, Randomized Controlled Trial
Phase 3CompletedBeijing Tiantan Hospital
2
impact
Improve Acute Reperfusion Treatment Quality for Stroke in China
N/ACompletedBeijing Tiantan Hospital
2
impact
Recombinant Human Prourokinase（rhPro-UK）for Injection Versus Standard Medical Treatment for Acute Mild Ischemic Stroke (NIHSS≤5) Within 4.5 Hours After Symptom Onset
Phase 3CompletedBeijing Tiantan Hospital
2
impact
Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE (RETRACE-II): A Randomized, Double-Blind, Sham-Controlled, Phase 2 Pilot Trial
N/ACompletedBeijing Tiantan Hospital
1
impact
Low-Frequency REpetitive TRanscranial Magnetic Stimulation in ACute Ischemic StrokE Within 48 Hours (RETRACE-I): A Randomized, Open-label, Evaluator-blinded, Phase 2 Pilot Trial
N/ACompletedBeijing Tiantan Hospital
1
impact
Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial
Phase 2CompletedJiangsu Simcere Pharmaceutical Co., Ltd.
1
impact
Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial
Phase 3CompletedJiangsu Simcere Pharmaceutical Co., Ltd.
1
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of RP902 Tablets in the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease
Phase 2Not Yet RecruitingRisen (Suzhou) Pharma Tech Co., Ltd.
0
impact
A Multicenter, Prospective, Non-Randomized, Parallel-Group, Post-Marketing Observational Patient Registry Study to Evaluate the Safety of Intravenous Thrombolysis With Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection (rhTNK-tPA, Mingfule®) Compared With Recombinant Tissue Plasminogen Activator (Rt-PA, Actilyse®) in Patients With Acute Ischemic Stroke
N/ANot Yet RecruitingCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
0
impact
A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke
Phase 2RecruitingKunming Pharmaceuticals, Inc.
0
impact
Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX): a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial
Phase 3Not Yet RecruitingBeijing Tiantan Hospital
0
impact
Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-B )
Phase 2RecruitingYongjun Wang
0
impact
Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-A )
Phase 2CompletedBeijing Tiantan Hospital
0
impact
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.
Phase 2UnknownKunming Pharmaceuticals, Inc.
0
impact
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, and PK Characteristics of SIM1910-09 After Single/Multiple Dosing in Healthy Chinese Volunteers
Phase 1CompletedJiangsu Simcere Pharmaceutical Co., Ltd.
0
impact